Technical Data
B5001-61A
BTLA (B- and T-lymphocyte Attenuator, B- and T-lymphocyte-associated Protein, CD272)
|
Technical Data |
|
B5001-61A |
BTLA (B- and T-lymphocyte Attenuator, B- and T-lymphocyte-associated Protein, CD272) |
|
|
Description: B and T lymphocyte attenuator (BTLA) is a 289aa recently identified inhibitory receptor that provides crucial activating or attenuating signals for T cells. It is a third member of co-inhibitory receptors of the CD28 immunoglobulin superfamily with similarities to (CTLA)-4 and (PD)-1 and interacts with a B7 homolog, B7H4. BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation. It remains expressed on Th1 cells but not Th2 cells. BTLA is a unique co-receptor which interacts with the tumor necrosis factor receptor superfamily member herpesvirus entry mediator (HVEM) and this interaction is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response and might also play an important role in the maintenance of T cell tolerance. Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 3-5ug/ml Optimal dilutions to be determined by the researcher. Positive Control: Human spleen lysate Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. |
|
|||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||